홈ATBPF • OTCMKTS
add
Antibe Therapeutics Ord Shs
시장 뉴스
재무
손익계산서
수익
순이익
| (CAD) | 2023년 12월info | 전년대비 변동 |
|---|---|---|
수익 | — | — |
운영비 | 459.60만 | -1.42% |
순이익 | -421.30만 | 2.39% |
순이익률 | — | — |
주당 수익 | -0.08 | 0.50% |
EBITDA | — | — |
유효 세율 | — | — |
대차대조표
총자산
총부채
| (CAD) | 2023년 12월info | 전년대비 변동 |
|---|---|---|
현금 및 단기 투자 | 2490.60만 | -41.20% |
총자산 | 5636.20만 | -23.56% |
총부채 | 3042.50만 | -0.13% |
총자기자본 | 2593.70만 | — |
발행 주식 | 5266.54만 | — |
주가순자산비율 | 0.44 | — |
총자산이익률 | -19.71% | — |
자본이익률 | -41.30% | — |
현금 흐름
순현금흐름
| (CAD) | 2023년 12월info | 전년대비 변동 |
|---|---|---|
순이익 | -421.30만 | 2.39% |
영업 현금 흐름 | -384.50만 | -6.66% |
투자 현금 흐름 | 1104.10만 | 1,975.38% |
자금 조달 현금 흐름 | — | — |
순현금흐름 | 719.60만 | 334.09% |
잉여 현금 흐름 | -246.88만 | -2,419.13% |
정보
Antibe Therapeutics was a Toronto-based pharmaceutical company that develops pain and inflammation-reducing drugs based on gaseous mediator technology. Antibe was founded by John L. Wallace, also a co-founder of NicOx, the first company to develop drugs utilizing gaseous mediators. Founded in 2009, the company listed on the TSX Venture Exchange in 2013 and was moved to the Toronto Stock Exchange in November 2020. In 2015, Antibe acquired Citagenix, a distributor involved in regenerative medicine.
On June 1, 2020, the company announced positive results in the final Phase 2 trial of its first drug Otenaproxesul.
On March 29, 2021, the drug's Investigational New Drug application was cleared by the US Food and Drug Administration, allowing for human trials.
In May 2024 the company went bankrupt and its stock was delisted from the Toronto Stock Exchange. Wikipedia
설립
2009
웹사이트
직원 수
11
